Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: The randomized MabEase study by Lugtenburg, P.J. (Pieternella) et al.
haematologica | 2017; 102(11) 1913
Received: June 2, 2017.
Accepted: September 14, 2017.
Pre-published: September 21, 2017.
©2017 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright.
All rights are reserved to the Ferrata Storti Foundation. Use of
published material is allowed under the following terms and
conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode. 
Copies of published material are allowed for personal or inter-
nal use. Sharing published material for non-commercial pur-
poses is subject to the following conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode,
sect. 3. Reproducing and sharing published material for com-
mercial purposes is not allowed without permission in writing
from the publisher.
Correspondence: 
p.lugtenburg@erasmusmc.nl
Ferrata Storti
Foundation
EUROPEAN
HEMATOLOGY
ASSOCIATION
Haematologica 2017
Volume 102(11):1913-1922
ARTICLENon-Hodgkin Lymphoma
doi:10.3324/haematol.2017.173583
Check the online version for the most updated
information on this article, online supplements,
and information on authorship & disclosures:
www.haematologica.org/content/102/11/1913
IIntravenous rituximab plus chemotherapy is standard treatment fordiffuse large B-cell lymphoma. A subcutaneous formulation of ritux-imab is expected to simplify and shorten drug preparation and
administration, and to reduce treatment burden. MabEase
(clinicaltrials.gov Identifier: 01649856) examined efficacy, safety and patient
satisfaction with subcutaneous rituximab plus chemotherapy in treat-
ment-naïve patients with diffuse large B-cell lymphoma. Patients were
randomized 2:1 to subcutaneous rituximab (intravenous 375 mg/m2
cycle 1; subcutaneous 1,400 mg cycles 2-8) or intravenous rituximab (375
mg/m2 cycles 1-8) plus cyclophosphamide, doxorubicin, vincristine, and
prednisone every 14 or 21 days. The primary endpoint was investigator-
assessed complete response/unconfirmed complete response. Secondary
endpoints included safety, treatment satisfaction (Cancer Treatment
Satisfaction Questionnaire and Rituximab Administration Satisfaction
Questionnaire), time savings, and survival. Of 576 randomized patients,
572 (378 subcutaneous; 194 intravenous) received treatment. End of
induction complete response/unconfirmed complete response rates
were 50.6% (subcutaneous) and 42.4% (intravenous). After a median 
35 months, median overall, event-free and progression-free survivals
were not reached. Grade ≥3 adverse events (subcutaneous 58.3%; intra-
venous 54.3%) and administration-related adverse events (both groups
21%) were similar between arms. Injection-site reactions were more
common with subcutaneous injections (5.7% versus 0%, respectively).
Rituximab Administration Satisfaction Questionnaire scores for ‘impact
on activities of daily living’, ‘convenience’, and ‘satisfaction’ were
improved with subcutaneous versus intravenous injections; Cancer
Therapy Satisfaction Questionnaire scores were similar between arms.
Median administration time (6 minutes vs. 2.6 to 3.0 hours), chair/bed
and overall hospital times were shorter with subcutaneous versus intra-
venous rituximab. Overall, subcutaneous and intravenous rituximab had
similar efficacy and safety, with improved patient satisfaction and time
savings. 
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ABSTRACT
Introduction
Intravenous (IV) rituximab plus chemotherapy is stan-
dard treatment for diffuse large B-cell lymphoma
(DLBCL) and follicular lymphoma (FL)1,2 on the basis of
improved efficacy versus chemotherapy alone.3-8 In addi-
tion to the primary treatment goal of optimizing patient
outcomes, such as response rate, progression-free and
overall survival, simplifying treatment and reducing treat-
ment burden are also important aims for patients and
healthcare providers. Subcutaneous (SC) dosing has the
potential to simplify administration, reduce the treatment
burden for patients, and reduce resource utilization at the
treatment facility.9-13
To address these needs in patients with non-Hodgkin
lymphoma (NHL), a SC formulation of rituximab has
been developed. Two studies using a pharmacokinetic
and clinical bridging approach, SABRINA and
SparkThera, have demonstrated pharmacokinetic non-
inferiority for rituximab SC compared with the IV formu-
lation in patients with FL.14-16 In SABRINA, when given in
a three-weekly dosing schedule as first-line treatment,
geometric mean rituximab trough concentrations at cycle
7 were 83.13 mg/mL for rituximab IV and 134.58 mg/mL
for rituximab SC, with comparable efficacy and safety
between formulations.14,15 In addition, the phase Ib
SAWYER study demonstrated pharmacokinetic non-infe-
riority and similar safety profiles for rituximab SC and IV
(both with fludarabine and cyclophosphamide) in first-
line chronic lymphocytic leukemia patients.17,18 The accu-
mulating clinical data, along with the established efficacy
and safety of rituximab IV,19,20 supported the authoriza-
tion of rituximab SC for patients with NHL, and ritux-
imab SC has subsequently been approved in Europe and
elsewhere for the treatment of DLBCL and FL.21-23 The SC
formulation takes approximately  5 minutes to administer
versus 1.5 to 6 hours for rituximab IV,19,21 and studies have
confirmed that this new presentation offers improved
patient convenience and healthcare resource savings over
the IV form.13,24
Herein we report the final analysis of the MabEase
study in patients with previously untreated CD20+
DLBCL, an aggressive form of NHL that is treated with
curative intent. The objectives of MabEase were to exam-
ine the efficacy and safety of rituximab SC versus the IV
formulation as part of a rituximab plus cyclophos-
phamide, doxorubicin, vincristine, and prednisone (R-
CHOP) regimen. Patient satisfaction with treatment was
also assessed.
Methods 
Study design
MabEase (clinicaltrials.gov Identifier: 01649856) is a phase IIIb,
multicenter, randomized, open-label study. The study was con-
ducted in line with International Conference on Harmonisation
E6 guidelines for Good Clinical Practice and the Declaration of
Helsinki. The study protocol was approved by independent
ethics committees at each center. The first patient was enrolled
on 22 August 2012, and the data cut-off for the current analysis
was 18 September 2016. All patients provided written informed
consent. Additional methodological details are provided in the
Online Supplementary Appendix.
Patients
Eligible patients were aged 18–80 years with untreated histolog-
ically confirmed CD20+ DLBCL, International Prognostic Index
(IPI) 1–5 or IPI 0 with bulky disease (one lesion ≥7.5 cm), had at
least one bidimensionally measurable lesion ≥1.5 cm at its largest
dimension by computed tomography (CT), positron emission
tomography-CT (PET-CT), or magnetic resonance imaging (MRI),
had adequate hematologic function, and Eastern Cooperative
Oncology Group (ECOG) performance status ≤2 (detailed inclu-
sion/exclusion criteria are supplied in the Online Supplementary
Appendix).
Randomization 
Patients were randomized 2:1 via a centralized interactive
voice/web response system to receive rituximab SC or IV, and
were stratified according to age (<60 or ≥60 years), IPI risk catego-
ry (low, low-intermediate, high-intermediate, high), and
chemotherapy regimen (CHOP-14, CHOP-21).
Procedures
All patients were scheduled to receive eight cycles of rituximab
in accordance with the prescribing information for rituximab in
DLBCL.19-21 In addition, patients received six to eight cycles of
CHOP chemotherapy every 14 (CHOP-14) or 21 (CHOP-21) days
(see the Online Supplementary Appendix). The planned CHOP regi-
men for each patient was chosen by the center prior to random-
ization. However, patients scheduled to receive eight cycles of
CHOP who achieved a complete response (CR)/unconfirmed
complete response (CRu) after cycle 4 could be reduced to two
additional rituximab plus CHOP cycles (for a total of six CHOP
cycles), followed by two rituximab monotherapy cycles (for a
total of eight rituximab cycles). Patients randomized to rituximab
SC received rituximab IV 375 mg/m2 on day one of cycle 1, then
rituximab SC 1,400 mg on day one of the subsequent seven cycles
(eight rituximab doses in total). Patients randomized to the IV arm
received rituximab 375 mg/m2 on day one of each cycle. All
patients received rituximab IV during cycle 1 in order to allow
appropriate intervention in the event of an administration-related
reaction (ARR). 
Outcomes
The primary endpoint was investigator-assessed CR/CRu rate
according to Cheson 1999 criteria25 at the end of induction (EOI)
in the intent-to-treat (ITT) population.
Secondary endpoints included patient satisfaction measured by
the Cancer Therapy Satisfaction Questionnaire (CTSQ) and
Rituximab Administration Satisfaction Questionnaire (RASQ) and
time savings; namely rituximab administration time, chair/bed
time, and hospital time. Other secondary endpoints were progres-
sion-free survival (PFS), event-free survival (EFS), disease-free sur-
vival (DFS), and overall survival (OS). The end of the study was
defined as the last patient visit in the follow-up period when all
patients had been followed for at least 24 months after their last
dose of study treatment.
Statistical analyses 
This was a descriptive study designed to exclude major differ-
ences in efficacy between treatment arms as measured by
CR/CRu rates. There was no formal statistical hypothesis for
treatment comparison. The calculated sample size (600 patients)
was based on the primary endpoint, and no power calculation was
performed for PFS.
The final analysis was performed in the ITT population when
the last patient had completed at least 24 months of follow up
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after the EOI, or when one of the following had been documented
for all randomized patients: disease recurrence, withdrawal from
study, loss to follow up or death, or whichever occurred first. 
An exploratory analysis was conducted to investigate potential
correlations between the incidence of adverse events (AEs) and
serious adverse advents (SAEs) in different body surface area
(BSA) categories and age, sex, or type of AE (MedDRA v17.1
System Organ Class preferred terms).
Results
Study population
Overall, 576 patients were enrolled and randomized
(SC, 381; IV, 195) from 151 in- or outpatient treatment
centers in 25 countries. Of these, 572 received at least one
dose of rituximab; however, nine patients randomized to
receive rituximab SC only received the first rituximab IV
infusion. The safety population therefore comprised 369
patients in the SC arm and 203 in the IV arm (369 and 188,
respectively, from cycle 2 onwards). The ITT population
comprised 519 patients (SC, 342; IV, 177; Figure 1).
Baseline demographics and disease characteristics were
balanced between treatment groups (Table 1).
Of 576 randomized patients, 102 (SC, 67 [17.6%]; IV, 35
[17.9%]) discontinued study treatment before the end of
cycle 8, predominantly because of AEs (SC, 36 [9.4%]; 
IV, 15 [7.7%]), and 217 patients (SC, 146 [38.3%]; IV, 71
[36.4%]) withdrew from the study altogether, predomi-
nantly because of death (SC, 73 [19.2%]; IV, 30 [15.4%];
Figure 1). In the randomized patient population, 311 of
381 SC patients and 159 of 195 IV patients completed the
treatment period. There were 217 (69.8%) SC patients and
117 (73.6%) IV patients still in follow up at the end of the
study.
The median duration of rituximab exposure was 
4.9 months in both groups (safety population). Overall,
82.2% of patients received eight rituximab cycles. Median
durations of CHOP exposure were 4.6 and 4.4 months in
the rituximab SC and IV arms, respectively. Overall,
85.7%, 47.4% and 46.7% of patients received six, seven,
and eight CHOP cycles, respectively.
Efficacy
In the ITT population at EOI, rates of investigator-
assessed CR/CRu (95% CI) were 50.6% (45.3%–55.9%)
and 42.4% (35.1%–49.7%), P=0.076, in the SC and IV
groups, respectively. Partial response (PR) and progressive
disease (PD) rates were similar between treatment arms.
CR/CRu rates (95% CI) for all randomized patients were
45.7% (40.7%–50.7%) for rituximab SC and 38.5%
(31.6%–45.3%) for IV, P=0.099. When stratified by age,
sex, BSA, CHOP regimen, and IPI score, statistically signif-
icantly higher CR/CRu rates with SC treatment versus IV
were seen in patients with low-intermediate IPI scores
along with a trend towards higher rates in patients aged
≥60 years (Table 2). Overall, CR/CRu rates were higher in
patients receiving CHOP-21 than CHOP-14 (Table 2),
although the latter regimen was used in only small num-
bers of patients.
SC vs. IV rituximab plus CHOP in 1st line DLBCL
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Figure 1. Patient disposition. *Nine
patients randomized to SC only received the
first IV infusion and were analyzed as IV in
the safety population. AE: adverse event;
ITT: intent-to-treat; IV: intravenous: SC: sub-
cutaneous; PD: progressive disease; SD:
stable disease.
After a median follow-up of 35 months, median survival
in the ITT population was not reached for PFS, EFS, DFS
or OS. Statistical analyses showed no significant differ-
ences between treatment groups (Figure 2). At the time of
the final data lock, 56 of 342 rituximab SC patients
(16.4%) had died, while 22 of 177 (12.4%) rituximab IV
patients had died. Analysis of PFS and EFS showed that
72.2% of SC and 78.5% of IV patients had not progressed,
relapsed or died, while 66.1% of SC and 71.2% of IV
patients had not experienced an event (Figure 2). PFS was
also generally similar between treatments for the sub-
groups with high SC CR/CRu rates (aged ≥60 years and
with low-intermediate IPI scores; Table 2; Online
Supplementary Appendix), although a higher proportion of
SC patients receiving CHOP-14 had progressed, relapsed
or died (14/36; 38.9% vs. 2/22; 9.1%; P=0.041). In addi-
tion, significantly higher proportions of SC patients with
low BSA had progressed, relapsed or died (43/115; 37.4%
vs. 9/56; 16.1%; P=0.01) or experienced an event (51/115;
44.3% vs. 13/56; 23.2%; P=0.02).
At 24 months of follow up, PFS (95% CI) was 75.0%
(69.9%–79.4%) in the SC group and 81.5% (74.7%–
86.6%) in the IV group (P=0.175), and EFS 
(95% CI) was 68.6% (63.3%–73.4%) and 73.4% (66.0%–
79.4%), respectively (P=0.456).
Safety 
Safety profiles were similar between arms, with no
unexpected safety signals (Online Supplementary Appendix).
Most AEs were grade 2 or 3 (339 [60.9%] of 557 patients
in the safety population with cycle 2 dosing or beyond
completed). In cycle 2 or later (all patients received ritux-
imab IV in cycle 1), 58.3% of SC and 54.3% of IV patients
experienced at least one AE of grade ≥3. ARRs were
reported in 20.9% of SC patients and 21.3% of IV patients
on or after cycle 2. Ten patients (2.7%) receiving rituximab
SC experienced an ARR of grade ≥3 on or after cycle 2,
compared with nine patients (4.8%) receiving IV. Injection
site reactions were reported by 5.7% of patients receiving
SC therapy; there were no such reactions with IV admin-
istration (P=0.0002). One injection site reaction (an
episode of injection site pain in the SC group) was grade
≥3; the remainder were grade <3.
In cycle 2 or later, 141 SC (38.2%) and 62 IV patients
(33.0%) reported at least one SAE, most commonly febrile
neutropenia (FN), neutropenia, and pneumonia. A higher
proportion of patients experienced FN as an SAE in the SC
versus the IV arm (11.7% vs. 6.4%, P=0.0515), consistent
with the higher incidence of grade 3/4 FN in the SC arm
(12.5% vs. 6.9%, P=0.0575).
A similar proportion of patients in each group in the
safety population discontinued rituximab treatment
because of AEs (SC, 30 [8.1%]; IV, 19 [9.4%]), the most
common of which were infections and infestations (2.4%
and 2.5% of patients in the SC and IV groups, respective-
ly; all treatment cycles). When cycle 1 was excluded, dis-
continuation rates were 7.9% for SC and 5.3% for IV rit-
uximab; infection and infestation rates were 2.4% (SC)
and 1.1% (IV). More SC patients (138 [37.4%]) had an
interruption/delay in their rituximab treatment due to AEs
when compared with the IV arm (56 [27.6%]; safety pop-
ulation, all cycles). The most common reasons (>2% of
patients) were neutropenia (SC, 34 [9.2%]; IV, 14 [6.9%]),
FN (SC, 13 [3.5%]; IV, 1 [0.5%]), pneumonia (SC, 8 [2.2%];
IV, 6 [3.0%]), neutrophil count decreased (SC, 20 [5.4%];
IV, 8 [3.9%]), and white blood cell count decreased (SC, 10
[2.7%]; IV, 3 [1.5%]).
Death due to treatment-emergent AEs (i.e., grade 5 AE)
was reported in 32 patients in the SC group (8.7%) and 14
in the IV group (6.9%). The main causes were infections
and infestations (SC, 14 [3.8%]; IV, 4 [2.0%]), cardiac dis-
orders (SC, 4 [1.4%]; IV, 4 [2.0%]), and respiratory, tho-
racic, and mediastinal disorders (SC, 2 [0.5%]; IV, 3
[1.5%]).
In the exploratory analysis, treatment effect on grade ≥3
AEs and SAEs (i.e., rituximab SC vs. IV) was not modified
by BSA, age group or sex (Online Supplementary Appendix).
Treatment satisfaction
Mean RASQ scores for 'impact on activities of daily liv-
ing', 'convenience', and 'satisfaction' were improved with
SC versus IV rituximab. Overall, 428 patients (SC, 284; IV,
144) completed the RASQ at cycle 7 and were included in
the RASQ analysis. The mean RASQ scores were higher
across all domains for rituximab SC versus IV (Table 3),
with mean satisfaction scores of 89.6 and 77.4 for the SC
and IV groups, respectively (Figure 3). More patients in
the rituximab SC group versus the IV group thought that
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Table 1. Patient baseline demographics and disease characteristics
(safety population). 
Characteristic                          Rituximab SC plus       Rituximab IV plus 
                                                          CHOP                          CHOP
                                                        (n=369)                       (n=203)
Median age, years (range)                64.0 (18-80)                     64.0 (24-80)
<60                                                          142 (38.5)                         79 (38.9)
≥60                                                          227 (61.5)                        124 (61.1)
Sex
Male                                                        204 (55.3)                        103 (50.7)
Female                                                   165 (44.7)                        100 (49.3)
Median BSA, m2 (range)                 1.83 (1.35-2.62)               1.84 (1.27-2.79)
BSA
Low (≤1.7)                                          122 (30.4)                         59 (29.1)
Medium (>1.7-≤1.9)                         119 (32.2)                         68 (33.5)
High (>1.9)                                         138 (37.4)                         76 (37.4)
ECOG PS
0                                                               180 (48.8)                        105 (51.7)
1                                                               148 (40.1)                         73 (36.0)
2                                                                41 (11.1)                          25 (12.3)
Ann Arbor stage
I–II                                                          122 (33.1)                         61 (30.0)
III–IV                                                      247 (66.9)                        142 (70.0)
IPI score                                                            
Low/low-intermediate                        224 (60.7)                        126 (62.1)
High/high-intermediate                      145 (39.3)                         77 (37.9)
Chemotherapy regimen
CHOP-14                                                  36 (9.8)                            22 (10.8)
CHOP-21                                                333 (90.2)                        181 (89.2)
Data are n (%), unless otherwise indicated. BSA: body surface area; CHOP: cyclophos-
phamide, doxorubicin, vincristine, and prednisone; CHOP-14: CHOP 14-day cycle;
CHOP-21: CHOP 21-day cycle; ECOG PS: Eastern Cooperative Oncology Group per-
formance status; IPI: International Prognostic Index; IV: intravenous; SC: subcutaneous.
. 
the length of time taken for the SC injection/IV infusion
was 'just right' (78.9% SC vs. 57.6% IV). When patients
in the SC group were asked which treatment they would
prefer, if given the option, 90.8% stated a preference for
SC over IV.
CTSQ scores were similar between arms (Figure 3 and
Table 3). A total of 421 patients were included in the
CTSQ analysis, with 421 (280 SC and 141 IV) completing
the questionnaire at cycle 7. The mean CTSQ satisfaction
score and scores for individual domains were similar
between the treatment arms (Table 3). RASQ and CTSQ
results for cycle 3 were similar to those for cycle 7.
Time savings
The median administration time (cycles 2–8) was sub-
stantially shorter for SC (6 minutes) than IV rituximab
(range: 2.6 to 3.0 hours). Chair/bed and overall hospital
times were also shorter with SC treatment. In cycle 2,
82.9% of patients in the SC arm had a chair/bed time 
≤4 hours, whereas 61.2% in the IV arm had a chair/bed
SC vs. IV rituximab plus CHOP in 1st line DLBCL
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Figure 2. Secondary time-to-event
endpoints for rituximab SC and ritux-
imab IV (intent-to-treat population).
Analyses presented are (A) progres-
sion-free survival, (B) event-free sur-
vival, (C) disease-free survival, and 
(D) overall survival. CI: confidence
interval; DFS: disease-free survival;
EFS: event-free survival; HR: hazard
ratio; IV: intravenous; OS: overall sur-
vival; PFS, progression-free survival;
SC: subcutaneous.
A
B
C
D
time ≥4 hours. For each cycle from cycle 2 onwards, a
higher proportion of SC than IV patients spent <2 hours in
a chair/bed receiving rituximab (ranges: 27%–56% SC 
vs. <1%–5% IV). In cycle 2, 64.8% of SC patients required 
≤6 hours of hospital time overall, whereas 51.6% of those
receiving rituximab IV required ≥6 hours.
Discussion
MabEase was a randomized, phase IIIb study designed
to exclude major differences in efficacy and safety
between rituximab SC and IV treatment arms in newly
diagnosed DLBCL patients treated with R-CHOP. The pri-
mary endpoint results indicated similar efficacy of the rit-
uximab SC and IV formulations in our overall study pop-
ulation.
We note that patient demographics in MabEase differed
from those in many key trials of  R-CHOP in DLBCL
patients. For example, the patient population in the
MabThera International Trial group (MInT) study was
younger (18–60 years), with low IPI risk scores,4 whereas
the populations in the LNH98.53 LNH03-6B,26 and ritux-
imab with CHOP over age 60 years (RICOVER-60)8 stud-
ies were older (60–80 years). However, we suggest that
comparisons of outcomes with these studies, although
indirect, are valid and informative once demographic dif-
ferences are taken into consideration.
Overall, previous trials of R-CHOP regimens including
rituximab IV reported CR/CRu rates ranging from 58% to
86% in patients with previously untreated DLBCL.3,4,8,26,27
The CR/CRu rates in our study (SC, 50.6%; IV, 42.4%)
were lower, which may relate to the number of patients in
the ITT population who did not complete the planned
course of treatment. The MabEase ITT population includ-
ed all patients who completed a baseline assessment and
at least one on-treatment efficacy assessment, with the
first efficacy assessment conducted at interim staging at
the end of cycle 4. However, approximately 18% of
patients discontinued study treatment before the end of
cycle 8, predominantly because of AEs. For SC and IV
patients who completed all eight cycles of induction,
P. Lugtenburg et al.
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Table 2. Efficacy endpoints at EOI treatment. 
Efficacy endpoint, % (95% CI) N Rituximab SC plus CHOP* N Rituximab IV plus CHOP P
ITT population
CR/CRu 342 50.6 (45.3-55.9) 177 42.4 (35.1-49.7) 0.076
PR 342 31.6 (26.7-36.8) 177 35.6 (28.6-43.1) -
PD 342 3.8 (2.0-6.4) 177 6.2 (3.1-10.8) -
ORR 342 82.2 (77.7-86.1) 177 78.0 (71.1-83.8) -
All-randomized population
CR/CRu 381 45.7 (40.7-50.7) 195 38.5 (31.6-45.3) 0.099
Subgroups 
(all-randomized population)
Age (years)
<60 147 42.9 (34.9-50.9) 76 40.8 (29.7-51.8) 0.767
≥60 234 47.4 (41.0-53.8) 119 37.0 (28.3-45.6) 0.062
Sex
Male 209 46.9 (40.1-53.7) 100 37.0 (27.5-46.5) 0.102
Female 172 44.2 (36.8-51.6) 95 40.0 (30.1-49.9) 0.508
CHOP regimen
CHOP-14 36 41.7 (25.6-57.8) 22 22.7 (5.2-40.2) 0.146
CHOP-21 345 46.1 (40.8-51.3) 173 40.5 (33.1-47.8) 0.224
IPI score
Low 118 50.0 (41.0-59.0) 61 54.1 (41.6-66.6) 0.603
Low-intermediate 114 52.6 (43.5-61.8) 57 35.1 (22.7-47.5) 0.031
High-intermediate 94 41.5 (31.5-51.4) 47 31.9 (18.6-45.2) 0.272
High 55 29.1 (17.1-41.1) 30 23.3 (8.2-38.5) 0.569
BSA (m2)
Low (≤1.7) 115 44.3 (35.3-53.4) 56 42.9 (29.9-55.8) 0.854
Medium (1.7-1.9) 123 45.5 (36.7-54.3) 65 38.5 (26.6-50.3) 0.353
High (>1.9) 143 46.9 (38.7-55.0) 74 35.1 (24.3-46.0) 0.099
*Three patients initially recorded as CR/CRu in the SC arm subsequently had their response downgraded to PR due to bone marrow data analysis. BSA: body surface area; CHOP:
cyclophosphamide, doxorubicin, vincristine, and prednisone; CHOP-14: CHOP 14-day cycle; CHOP-21: CHOP 21-day cycle;  CI: confidence interval; CR: complete response; CRu:
complete response unconfirmed; EOI: end of induction; IPI: International Prognostic Index; ITT: intent-to-treat; IV: intravenous; ORR: overall response rate; PD: progressive disease;
PR: partial response; SC: subcutaneous.
CR/CRu rates were 57% and 47%, respectively. In addi-
tion, distinguishing PR from CRu using a CT scan alone is
difficult. Current criteria recommend using PET scans
where possible in order to better delineate disease extent
and treatment response in DLBCL.28 However, due to lim-
ited PET availability, the MabEase study protocol prespec-
ified the use of CT scans only for all tumor assessments.
This may also have contributed to the apparently low CR
rate. Another limitation was the lack of centralized radio-
logic review. For these aforementioned reasons the CR
rates in MabEase should be interpreted with caution.
Despite the lower CR rate, the overall response rate in our
study (CR/CRu plus PR; approximately 80%) was similar
to observations in previous studies.3,4,8,26
Some trends towards higher CR/CRu rates were seen
with SC treatment in some subgroups, but these did not
translate into improvements in PFS or EFS, with a small
number of subgroups showing increased rates of progres-
sion, relapse or death, or increased event rates. We note
that these analyses were exploratory only, however, and
that patient numbers in the subgroups were too small to
permit any conclusions to be drawn. In particular, very
SC vs. IV rituximab plus CHOP in 1st line DLBCL
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Figure 3. Patient satisfaction and pref-
erence. (A) Patient satisfaction
assessed by (i) RASQ and (ii) CTSQ at
cycles 3 and 7, (B) Time taken to receive
SC injection/IV infusion (RASQ individual
question) at cycle 7, (C) Treatment pref-
erences (RASQ individual question) at
cycles 3 and 7. CTSQ: Cancer Therapy
Satisfaction Questionnaire; IV: intra-
venous; RASQ: Rituximab Administration
Satisfaction Questionnaire; SC: subcuta-
neous.
A
B
C
few patients (approximately 10%) received CHOP-14 in
MabEase, and it is therefore not possible to draw mean-
ingful comparisons with response rates in the CHOP-21 or
overall populations. Survival results overall were similar
for both formulations in the ITT population. 
In MabEase, similar safety profiles were observed in the
SC and IV arms. There were no new safety signals, and
the rate of treatment-related deaths was comparable with
rates reported in other studies.3,8,26 ARRs with rituximab
have been well characterized in previous studies, particu-
larly during cycle 1.29 To minimize ARR risk, rituximab
was infused at a low initial rate, which was then increased
incrementally. All patients received rituximab IV during
cycle 1. Consistent with the reported SparkThera (phase
Ib) and SABRINA (phase III) studies,14-16 we observed a
higher rate of ARRs with rituximab SC versus IV. As
expected, injection site reactions were more common
with SC than with IV treatment, but these were mostly
mild/moderate (< grade 3) and manageable.
The most frequent SAE in this study was FN 
(SC, 11.7%; IV 6.4%), although there was no difference
between groups in rates of treatment discontinuation due
to AEs or infections. FN and grade 3 neutropenia were
more frequently reported in the rituximab SC arm, and we
do not have a comprehensive explanation for this obser-
vation. However, in DLBCL studies with rituximab dose
intensification, and thus higher rituximab serum levels,
more neutropenia and/or FN were also reported.30,31
Compared with other studies in DLBCL, the overall inci-
dence of FN in our study (9.9%) was similar to that report-
ed by Cunningham et al. among patients receiving the
CHOP-21 regimen (11%),27 and to specific analysis of FN
among the DLBCL cohort of the PrefMab crossover phase
IIIb study in which patients with DLBCL or FL received
rituximab SC and IV in different sequences (9.4%; data
not reported by Rummel et al.).24 Analysis of patient sub-
groups showed a trend towards higher incidence of AEs
and SAEs in patients with low BSA. These effects were
not significant, however, and no significant interaction
effect was found for AEs of grade ≥3 or SAEs for any of
the covariates (BSA, age, or sex).
CTSQ results showed that patients had similar levels
of satisfaction with the R-CHOP treatment when used
with either SC or IV rituximab, which is consistent with
CTSQ data obtained in the PrefMab study.24 However,
RASQ data suggested that most rituximab SC patients,
given the option, preferred to have the SC injection over
the IV infusion; again this finding reiterates the prefer-
ence for rituximab SC expressed by 80.7% of patients in
PrefMab.24 Consistent with our findings, in PrefMab, rit-
uximab SC scored more highly for satisfaction with ther-
apy (87.5% vs. 75.0% for IV), impact on activities of
daily living and convenience of therapy (both 83.3% vs.
58.3%).24 Of note, the CTSQ was designed for use in a
wide range of cancer types and stages.32 In contrast, the
RASQ was developed specifically for the assessment of
patients’ perceptions of the impact of treatment adminis-
tration route.33
The use of rituximab SC resulted in substantial savings
in clinic time. These findings concur with a time and
motion analysis based on data collected within the
MabCute study34 in patients with indolent NHL, which
evaluated aspects of SC and IV administration of ritux-
imab in real-world clinical practice.13 Reductions in chair
time could potentially reduce waiting lists, increase the
efficiency of oncology units, and increase the availability
of appointments. In addition, the healthcare practitioner
time gained could be deployed in other activities. Cost
minimization data from The Netherlands also indicate the
potential for cost savings with rituximab SC when com-
P. Lugtenburg et al.
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Table 3. Mean (SD) RASQ and CTSQ scores at cycles 3 and 7 (ITT RASQ and CTSQ populations). 
Domain Visit Rituximab SC Rituximab IV
RASQ
Physical impact Cycle 3 87.1 (12.9) 84.5 (15.1)
Cycle 7 86.2 (14.0) 81.5 (16.8)
Psychological impact Cycle 3 84.2 (14.2) 77.3 (17.4)
Cycle 7 85.7 (13.9) 78.7 (18.2)
Impact on activities of daily living Cycle 3 83.0 (16.8) 60.4 (20.0)
Cycle 7 83.8 (16.1) 57.4 (19.2)
Convenience Cycle 3 82.3 (13.5) 62.4 (19.8)
Cycle 7 82.3 (13.4) 60.1 (17.5)
Satisfaction Cycle 3 87.6 (12.9) 78.3 (16.9)
Cycle 7 89.6 (12.1) 77.4 (18.2)
CTSQ
Expectations of therapy Cycle 3 79.7 (17.8) 82.1 (18.1)
Cycle 7 79.4 (17.4) 82.9 (16.5)
Feelings about side effects Cycle 3 63.4 (18.7) 62.7 (21.2)
Cycle 7 60.7 (21.6) 57.6 (23.3)
Satisfaction with therapy Cycle 3 86.0 (11.1) 83.3 (12.6)
Cycle 7 85.9 (11.4) 83.6 (13.5)
CTSQ: Cancer Therapy Satisfaction Questionnaire; ITT: intent-to-treat; IV: intravenous; RASQ: Rituximab Administration Satisfaction Questionnaire;  SC: subcutaneous; SD: standard
deviation.
pared with IV dosing.35 Although reductions in clinic time
could also reduce the opportunity for healthcare profes-
sionals to provide patient support, the RASQ findings
indicated that patients felt that this factor did not compro-
mise their treatment, and that they had sufficient time to
discuss their treatment with their healthcare providers.
In conclusion, the MabEase study showed no major dif-
ferences between the efficacy of rituximab SC and IV ther-
apy in treatment-naïve patients with DLBCL. Overall,
safety was similar between arms but with a higher inci-
dence of FN and injection site reactions in the rituximab
SC arm. The higher RASQ scores in the rituximab SC arm
suggest that patient satisfaction, convenience, and effect
on daily living were improved with rituximab SC com-
pared with IV. Attempts to improve care for patients with
DLBCL, including short treatment intervals, consolidation
with high-dose chemotherapy and autologous stem cell
transplantation and replacement of rituximab with the
type II CD20 antibody obinutuzumab, have so far been
unsuccessful.29,36-38 Combined with previous evidence, the
results of this study provide support for the use of ritux-
imab SC in this setting.
Funding
This study was sponsored by F. Hoffmann-La Roche Ltd.
Editorial support under the direction of the lead author was pro-
vided by Cheryl Wright, PhD and Susan Browne, PhD, of
Gardiner-Caldwell Communications (Macclesfield, UK) and
funded by F. Hoffmann-La Roche Ltd.
SC vs. IV rituximab plus CHOP in 1st line DLBCL
haematologica | 2017; 102(11) 1921
References
1. Tilly H, Gomes da Silva M, Vitolo U, et al.
Diffuse large B-cell lymphoma (DLBCL):
ESMO clinical practice guidelines for diag-
nosis, treatment and follow-up. Ann
Oncol. 2015;26(Suppl 5):v116-125.
2. Dreyling M, Ghielmini M, Marcus R, Salles
G, Vitolo U, Ladetto M. Newly diagnosed
and relapsed follicular lymphoma: ESMO
clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 2014;
25(Suppl 3):iii76-82.
3. Coiffier B, Thieblemont C, Van Den Neste
E, et al. Long-term outcome of patients in
the LNH-98.5 trial, the first randomized
study comparing rituximab-CHOP to stan-
dard CHOP chemotherapy in DLBCL
patients: a study by the Groupe d'Etudes
des Lymphomes de l'Adulte. Blood.
2010;116(12):2040-2045.
4. Pfreundschuh M, Trumper L, Osterborg A,
et al. CHOP-like chemotherapy plus ritux-
imab versus CHOP-like chemotherapy
alone in young patients with good-progno-
sis diffuse large-B-cell lymphoma: a ran-
domised controlled trial by the MabThera
International Trial (MInT) Group. Lancet
Oncol. 2006;7(5):379-391.
5. Marcus R, Imrie K, Belch A, et al. CVP
chemotherapy plus rituximab compared
with CVP as first-line treatment for
advanced follicular lymphoma. Blood.
2005;105(4):1417-1423.
6. Coiffier B, Lepage E, Briere J, et al. CHOP
chemotherapy plus rituximab compared
with CHOP alone in elderly patients with
diffuse large-B-cell lymphoma. N Engl J
Med. 2002;346(4):235-242.
7. Habermann TM, Weller EA, Morrison VA,
et al. Rituximab-CHOP versus CHOP alone
or with maintenance rituximab in older
patients with diffuse large B-cell lym-
phoma. J Clin Oncol. 2006;24(19):3121-
3127.
8. Pfreundschuh M, Schubert J, Ziepert M, et
al. Six versus eight cycles of bi-weekly
CHOP-14 with or without rituximab in
elderly patients with aggressive CD20+ B-
cell lymphomas: a randomised controlled
trial (RICOVER-60). Lancet Oncol.
2008;9(2):105-116.
9. Lundin J, Kimby E, Bjorkholm M, et al.
Phase II trial of subcutaneous anti-CD52
monoclonal antibody alemtuzumab
(Campath-1H) as first-line treatment for
patients with B-cell chronic lymphocytic
leukemia (B-CLL). Blood. 2002;100(3):768-
773.
10. Pivot X, Gligorov J, Muller V, et al.
Preference for subcutaneous or intravenous
administration of trastuzumab in patients
with HER2-positive early breast cancer
(PrefHer): an open-label randomised study.
Lancet Oncol. 2013;14(10):962-970.
11. Shpilberg O, Jackisch C. Subcutaneous
administration of rituximab (MabThera)
and trastuzumab (Herceptin) using
hyaluronidase. Br J Cancer. 2013;109(6):
1556-1561.
12. Stilgenbauer S, Zenz T, Winkler D, et al.
Subcutaneous alemtuzumab in fludara-
bine-refractory chronic lymphocytic
leukemia: clinical results and prognostic
marker analyses from the CLL2H study of
the German Chronic Lymphocytic
Leukemia Study Group. J Clin Oncol.
2009;27(24):3994-4001.
13. De Cock E, Kritikou P, Sandoval M, et al.
Time savings with rituximab subcutaneous
injection versus rituximab intravenous
infusion: a time and motion study in eight
countries. PLoS One. 2016;11(6):e0157957.
14. Davies A, Merli F, Mihaljevic B, et al.
Pharmacokinetics and safety of subcuta-
neous rituximab in follicular lymphoma
(SABRINA): stage 1 analysis of a ran-
domised phase 3 study. Lancet Oncol.
2014;15(3):343-352.
15. Davies AJ, Merli F, Mihaljevic B, et al.
Efficacy and safety of subcutaneous ritux-
imab versus intravenous rituximab for first-
line treatment of follicular lymphoma
(SABRINA): a randomised, open-label,
phase 3 trial. Lancet Haematol. 2017;
4(6):e272–e282.
16. Salar A, Avivi I, Bittner B, et al. Comparison
of subcutaneous versus intravenous admin-
istration of rituximab as maintenance treat-
ment for follicular lymphoma: results from
a two-stage, phase IB study. J Clin Oncol.
2014;32(17):1782-1791.
17. Assouline S, Buccheri V, Delmer A, et al.
Pharmacokinetics and safety of subcuta-
neous rituximab plus fludarabine and
cyclophosphamide for patients with chron-
ic lymphocytic leukaemia. Br J Clin
Pharmacol. 2015;80(5):1001-1009.
18. Assouline S, Buccheri V, Delmer A, et al.
Pharmacokinetics, safety, and efficacy of
subcutaneous versus intravenous rituximab
plus chemotherapy as treatment for chron-
ic lymphocytic leukaemia (SAWYER): a
phase 1b, open-label, randomised con-
trolled non-inferiority trial. Lancet
Haematol. 2016;3(3):e128-e138.
19. MabThera Summary of Product
Characteristics. European Medicines
Agency; 2017 [updated 6 July 2017; cited 25
September 2017]. Available from:
http://www.ema.europa.eu/docs/en_GB/d
ocument_ l ibrary/EPAR_-_Product_
Information/human/000165/WC50002582
1.pdf. Last accessed 25 September 2017.
20. Rituxan Highlights of Prescribing
Information. US Food and Drug
Administration; 2012 [updated October
2012; cited 25 September 2017]. Available
from: http: // www. accessdata. fda. gov/
drugsatfda_docs/label/2012/103705s5367s
5388lbl.pdf. Last accessed 25 September
2017.
21. MabThera 1400 mg Solution for
Subcutaneous Injection. European
Medicines Agency; 2017 [updated 15
August 2017; cited 25 September 2017].
Available from:
<http://www.medicines.org.uk/emc/medi-
cine/28732/SPC/MabThera+1400+mg+Sol
ution+for+Subcutaneous+Injection>. Last
accessed 25 September 2017.
22. Rituximab (MabThera SC) Australian
Public Assessment Report. Therapeutic
Goods Administration; 2014 [updated 13
October 2014; cited 25 September 2017].
Available from:
https://www.tga.gov.au/auspar/auspar-rit-
uximab-3. Last accessed 25 September
2017.
23. Rituxan SC Product Monograph.
Hoffmann-La Roche Ltd.; 2016 [updated 9
September 2016; cited 25 September 2017].
Available from: http:// www. rochecana-
da.com/content/dam/roche_canada/en_C
A/documents/Research/ClinicalTrialsForm
s/Products/ConsumerInformation/Monogr
aphsandPublicAdvisories/RituxanSC/Ritux
anSC_PM_E.pdf. Last accessed 25
September 2017.
24. Rummel M, Kim TM, Aversa F, et al.
Preference for subcutaneous or intra-
venous administration of rituximab
among patients with untreated CD20+
diffuse large B-cell lymphoma or follicular
lymphoma: results from a prospective,
randomized, open-label, crossover study
(PrefMab). Ann Oncol. 2017;28(4):836-
842. 
25. Cheson BD, Horning SJ, Coiffier B, et al.
Report of an international workshop to
standardize response criteria for non-
Hodgkin's lymphomas. NCI Sponsored
International Working Group. J Clin Oncol.
1999;17(4):1244.
26. Delarue R, Tilly H, Mounier N, et al. Dose-
dense rituximab-CHOP compared with
standard rituximab-CHOP in elderly
patients with diffuse large B-cell lymphoma
(the LNH03-6B study): a randomised phase
3 trial. Lancet Oncol. 2013;14(6):525-533.
27. Cunningham D, Hawkes EA, Jack A, et al.
Rituximab plus cyclophosphamide, dox-
orubicin, vincristine, and prednisolone in
patients with newly diagnosed diffuse large
B-cell non-Hodgkin lymphoma: a phase 3
comparison of dose intensification with 14-
day versus 21-day cycles. Lancet.
2013;381(9880):1817-1826.
28. Cheson BD, Fisher RI, Barrington SF, et al.
Recommendations for initial evaluation,
staging, and response assessment of
Hodgkin and non-Hodgkin lymphoma: the
Lugano classification. J Clin Oncol.
2014;32(27):3059-3068.
29. Vogel WH. Infusion reactions: diagnosis,
assessment, and management. Clin J Oncol
Nurs. 2010;14(2):E10-21.
30. Murawski N, Pfreundschuh M, Zeynalova
S, et al. Optimization of rituximab for the
treatment of DLBCL (I): dose-dense ritux-
imab in the DENSE-R-CHOP-14 trial of the
DSHNHL. Ann Oncol. 2014;25(9):1800-
1806.
31. Lugtenburg PJ, de Nully Brown P, van der
Holt B, et al. Randomized phase III study
on the effect of early intensification of rit-
uximab in combination with 2-weekly
CHOP chemotherapy followed by ritux-
imab or no maintenance in patients with
diffuse large B-cell lymphoma: Results from
a HOVON-Nordic Lymphoma Group
study. J Clin Oncol. 2016;34(suppl; abstr
7504).
32. Trask PC, Tellefsen C, Espindle D, Getter
C, Hsu MA. Psychometric validation of the
cancer therapy satisfaction questionnaire.
Value Health. 2008;11(4):669-679.
33. Rule S, Briones J, Smith R, et al. Preference
for rituximab subcutaneous (SC) and intra-
venous (IV) among patients with CD20+
Non-Hodgkin's Lymphoma (NHL) com-
pleting the RASQ measure in randomized
phase III studies Prefmab and Mabcute.
Value Health. 2014;17(7):A537.
34. Rule S, Briones J, Carella AM, et al. A ran-
domized comparison of maintenance ther-
apy with subcutaneous rituximab for 2
years versus until progression in patients
with indolent non-Hodgkin’s lymphoma:
interim safety data from the Mabcute
Study. Blood. 2013;122(21):3052.
35. Bax P, Postma MJ. Cost-minimization of
MabThera intravenous versus subcuta-
neous administration. Value Health.
2013;16:A390-A391.
36. Stiff PJ, Unger JM, Cook JR, et al.
Autologous transplantation as consolida-
tion for aggressive non-Hodgkin's lym-
phoma. N Engl J Med. 2013;369(18):1681–
1690.
37. Schmitz N, Nickelsen M, Ziepert M, et al.
Conventional chemotherapy (CHOEP-14)
with rituximab or high-dose chemotherapy
(MegaCHOEP) with rituximab for young,
high-risk patients with aggressive B-cell
lymphoma: an open-label, randomised,
phase 3 trial (DSHNHL 2002-1). Lancet
Oncol. 2012;13(12):1250–1259.
38. Vitolo U, Trnêný M, Belada D, et al.
Obinutuzumab or rituximab plus
cyclophosphamide, doxorubicin, vin-
cristine, and prednisone in previously
untreated diffuse large B-cell lymphoma. J
Clin Oncol. 2017 Aug 10:JCO.2017733402.
[Epub ahead of print] 
P. Lugtenburg et al.
1922 haematologica | 2017; 102(11)
